Vorinostat
Recurrent Squamous Cell Carcinoma of the Hypopharynx
AIDS Malignancy ConsortiumSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Recurrent Squamous Cell Carcinoma of the Hypopharynx cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab National Cancer Institute (NCI) | Phase 1/2 | B |
Irinotecan AIDS Malignancy Consortium | Phase 1/2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | CCC |
Alvespimycin National Cancer Institute (NCI) | Phase 1 | CC |
View all 11 →
Same molecule, other indications
Vorinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →